Fahim Mohamed Ibrahim, Nassar Omaya Abdelhamid, Mansour Osman Mohamed, Ali Abdelmaksoud Mohamed, Mahmoud Ahmed-Mostafa, Allam Rasha Mahmoud, Kamal Amr
Department of Surgical Oncology, National Cancer Institute-Cairo University, Egypt.
Department of Surgical Oncology, National Cancer Institute-Cairo University, Egypt.
J Egypt Natl Canc Inst. 2018 Dec;30(4):139-141. doi: 10.1016/j.jnci.2018.10.003. Epub 2018 Nov 22.
Complete cytoreduction has been associated with survival benefit in the treatment of recurrent epithelial ovarian cancer (EOC). In this study, the aim is to investigate the role of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of recurrent EOC.
This is a descriptive (case series) study including 9 patients with recurrent EOC treated by CRS and HIPEC. They were treated and followed up between December 2011 and December 2017. The study was performed at The National Cancer Institute (NCI) - Cairo University (CU).
Postoperative death occurred in 2 cases, while recurrence occurred in one case. Six cases had smooth postoperative course and free follow-up. Median follow-up period was 39 months, ranging from 29 to 47 months. Median overall survival was 42 months while median disease-free survival was not reached.
Treatment of recurrent EOC by CRS and HIPEC appears to be promising. However, this line of treatment requires further evaluations and larger studies for better assessment of the potential survival benefits and possible complications.
在复发性上皮性卵巢癌（EOC）的治疗中，完全细胞减灭术与生存获益相关。本研究旨在探讨细胞减灭术（CRS）和热灌注化疗（HIPEC）在复发性EOC治疗中的作用。
这是一项描述性（病例系列）研究，纳入9例接受CRS和HIPEC治疗的复发性EOC患者。他们于2011年12月至2017年12月期间接受治疗及随访。该研究在开罗大学国家癌症研究所（NCI）进行。
2例患者术后死亡，1例复发。6例患者术后病程顺利，随访无异常。中位随访期为39个月，范围为29至47个月。中位总生存期为42个月，而中位无病生存期未达到。
CRS和HIPEC治疗复发性EOC似乎很有前景。然而，这一治疗方案需要进一步评估和更大规模的研究，以更好地评估潜在的生存获益和可能的并发症。
